ProCE Banner Activity

Frequently Asked Questions JAK Inhibitors in RA

Clinical Thought
What is the place of JAK inhibitors in the treatment of RA? Read expert answers to audience questions from a CCO Webinar on current best practices and emerging options for patients with RA.

Released: December 10, 2020

Expiration: December 09, 2021

No longer available for credit.

Share

Faculty

Stanley B. Cohen

Stanley B. Cohen, MD

Clinical Professor
Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director
Division of Rheumatology
Presbyterian Hospital
Dallas, Texas

Sheetal Desai

Sheetal Desai, MD, MSEd

Chief of Rheumatology
Program Director
University of California, Irvine
Irvine, California

Eric M. Ruderman

Eric M. Ruderman, MD

Professor
Northwestern University Feinberg School of Medicine
Clinical Practice Director
Northwestern Medical Group
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Gilead

Faculty Disclosure

Primary Author

Stanley B. Cohen, MD

Clinical Professor
Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director
Division of Rheumatology
Presbyterian Hospital
Dallas, Texas

Stanley B. Cohen, MD, has disclosed that he has received consulting fees from AbbVie, Gilead Sciences, and Pfizer and funds for research support from AbbVie, Gilead Sciences, Lilly, and Pfizer.

Sheetal Desai, MD, MSEd

Chief of Rheumatology
Program Director
University of California, Irvine
Irvine, California

Sheetal Desai, MD, MSEd, has disclosed that she has received consulting fees and fees for non-CME/CE services from Janssen.

Eric M. Ruderman, MD

Professor
Northwestern University Feinberg School of Medicine
Clinical Practice Director
Northwestern Medical Group
Chicago, Illinois

Eric M. Ruderman, MD, has disclosed that he has received consulting fees from AbbVie, Amgen, Gilead Sciences, Janssen, Lilly, Novartis, Pfizer, and Selecta.